期刊文献+

药物涂层球囊治疗冠状动脉原位病变的有效性及安全性

Efficacy and safety of drug-coated balloon in the treatment of de novo coronary artery disease
下载PDF
导出
摘要 目的探讨药物涂层球囊(drug-coated balloon,DCB)治疗冠状动脉原位病变的安全性和有效性。方法回顾性选择2021年2月至2022年6月在安徽医科大学附属安庆第一人民医院进行介入治疗的85例冠状动脉原位病变患者,根据介入治疗方法分为药物洗脱支架(drug-eluting stent,DES)组(n=45)和DCB组(n=40)。比较两组患者术前、术后即刻和术后6个月的最小管腔直径(minimal lumen diameter,MLD)和管腔狭窄程度,手术即刻成功率,术中并发症发生率,术后6个月的晚期管腔丢失(late lumen loss,LLL),术后6个月内主要不良心血管事件(major adverse cardiovascular event,MACE)发生率。结果DCB组术后即刻与术后6个月MLD小于DES组(P<0.001);DCB组术后即刻管腔狭窄程度大于DES组(P<0.001),术后6个月与DES组差异无统计学意义。DCB组手术即刻成功率为95.00%,与DES组(97.78%)差异无统计学意义。两组患者术中并发症发生率差异无统计学意义。DCB组术后6个月LLL、MACE发生率均低于DES组(P<0.05)。结论DCB治疗冠状动脉原位病变的即刻成功率较高,可明显改善动脉血管狭窄情况,且安全性较高。 Objective To explore the safety and efficacy of drug-coated balloon(DCB)in the treatment of de novo coronary artery disease.Methods A total of 85 patients with de novo coronary artery disease undergoing interventional therapy in Anqing First People’s Hospital Affiliated to Anhui Medical University from February 2021 to June 2022 were retrospectively included,and were divided into drug-eluting stent(DES)group(n=45)and DCB group(n=40)according to different interventional therapies.The minimal lumen diameter(MLD)and the degree of lumen stenosis before surgery,immediately after surgery and at 6 months after surgery,immediate success rate of surgery and incidence of intraoperative complications,late lumen loss(LLL)at 6 months after surgery,incidence of major adverse cardiovascular event(MACE)within 6 months after surgery were compared between the two groups.Results Immediately and at 6 months after surgery,MLD in DCB group was significantly shorter than that in DES group(P<0.001).Immediately after surgery,lumen stenosis in DCB group was significantly severer than that in DES group(P<0.001),but there was no significant difference between the two groups at 6 months after surgery.There was no significant difference in immediate success rate of surgery between DCB group and DES group(95.00%vs 97.78%).There was no significant difference in incidence of intraoperative complications between the two groups.At 6 months after surgery,incidences of LLL and MACE in DCB group were significantly lower than those in DES group(P<0.05).Conclusions DCB interventional therapy has high immediate success rate of surgery for de novo coronary artery disease,which can significantly improve arterial vascular stenosis,with good safety.
作者 程辉 彭杰成 伍万仕 江庆 CHENG Hui;PENG Jie-cheng;WU Wan-shi;JIANG Qing(Department of Cardiovascular Medicine,Anqing First People’s Hospital Affiliated to Anhui Medical University,Anqing 246000,Anhui,China)
出处 《中国临床医学》 2023年第6期1010-1014,共5页 Chinese Journal of Clinical Medicine
基金 皖南医学院教学医院科研基金(JXYY202028).
关键词 冠状动脉原位病变 药物涂层球囊 药物洗脱支架 主要不良心血管事件 de novo coronary artery disease drug-coated balloon drug-eluting stent major adverse cardiovascular event
  • 相关文献

参考文献5

二级参考文献69

  • 1柯元南,陈纪林.不稳定性心绞痛和非ST段抬高心肌梗死诊断与治疗指南[J].中华心血管病杂志,2007,35(4):295-304. 被引量:2156
  • 2Kastrati A, Schfimig A, Elezi S, et al. Predictive factors of restenosis after coronary stent placement. J Am Coll Cardiol, 1997, 30(6) : 1428-1456. 被引量:1
  • 3Laham R J, Carrozza JP, Berger C, et al. Long-term ( 4-to 6- year) outcome of Palmaz-Schatz stenting: paucity of late clinical stent-related problems. J Am Coil Cardiol, 1996, 28 ( 4 ) : 820- 826. 被引量:1
  • 4Scheller B, Speck U, Abramjuk C, et al. Paclitaxel balloon coating, a novel method for prevention and therapy of restenosis. Circulation, 2004, 110(7) : 810-814. 被引量:1
  • 5Sergie Z, Dangas GD. In-stent restenosis of bifurcation lesions: experience with drug-eluting balloons. Catheter Cardiovasc Interv, 2012, 79 ( 3 ) :397-398. 被引量:1
  • 6Cremers B, Toner JL, Schwartz LB, et al. Inhibition of neointimal hyperplasia with a novel zotarolimus coated balloon catheter. Clin Res Cardiol, 2012, 101(6) :469-476. 被引量:1
  • 7Loh JP, Barbash IM, Waksman R. The current status of drug- coated balloons in percutaneous coronary and peripheral interventions. EuroIntervention, 2013, 9(8) :979-988. 被引量:1
  • 8I-Iwang CW,Wu D, Edelman ER. Physiological transport forces govern drug distribution for stent-based delivery. Circulation, 2001, 104(5):600-605. 被引量:1
  • 9Scheller B, Speck U, Btihm M. Prevention of restenosis : is angioplasty the answer? Heart, 2007, 93 (5) :539-541. 被引量:1
  • 10Scheller B, Hehrlein C, Boeksch W, et al. Treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. N Engl J Med, 2006, 355(20) :2113-2124. 被引量:1

共引文献238

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部